Dacomitinib

Fact of Medicine
Brand Name: Vizimpro
Innovator Brand Name: Vizimpro
API: Dacomitinib
Packaging: 30 Tablets
Strength: 15/30/45mg
Manufacturer Name: Pfizer

Get Price

Description

Dacomitinib Medication

Dacomitinib is a kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). It is mainly used as a first treatment option if tumors have certain types of abnormal EGFR gene(s).

Dosage: The recommended vizimpro dose is 45 mg administered orally once daily, until the disease is progressive or unacceptable toxicity is noticed. It can be administered either with or without food. Take dacomitinib tablets at the same time each day. If the patient pukes or misses any particular dose, do not administer an additional dose or make up a missed dose but must continue with the next scheduled dose.

Side Effects: The most commonly reported dacomitinib side effects may include:

  • Rash
  • Diarrhea
  • Common cold
  • Dry skin
  • Dry, red, itchy eyes
  • Hair loss
  • Itching
  • Nail inflammation
  • Decreased appetite
  • Decreased weight
  • Mouth pain and sores

Warnings and Precautions:

  • Patients with dacomitinib tablets should be monitored for pulmonary symptoms indicative of pneumonitis or ILD.
  • Patients with the therapy of vizimpro 45 mg are advised to contact their doctor if they notice first signs of diarrhea. Patients are advised that intravenous hydration or anti-diarrheal drug may be needed to manage diarrhea.
  • Verify the pregnancy status of women of reproductive potential before initiating treating with vizimpro 30 mg. As this drug can cause fetal harm if administered to a pregnant woman.
  • Females of reproductive potential are advised to use effective contraception while therapy with dacomitinib 15 mg and for at least 17 days following the final dose. Advise women not to breastfeed while on treatment with vizimpro 15 mg and for 17 days following the last dose

More info

Storage: Store Dacomitinib at temperature 20 °C to 25 °C (68 °F to 77 °F). Keep Dacomitinib tablets and all medications out of the reach of children. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship VIZIMPRO at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the VIZIMPRO Tablets. Buying Procedure: In order to buy VIZIMPRO, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919650877511 or an Email to us at: info@theindianpharma.com along with your Identity Proof, Valid Prescription Letter and Medical Reports. Conclusion: The dacomitinib fda label drug was well tolerated as well as had antitumor activity in recipients with NSCLC who had previously progressed on chemo and an EGFR tyrosine kinase inhibitor.

FAQ

What is Vizimpro? Vizimpro is a prescription medication used in the treatment of patients with metastatic non-small-cell lung cancer. What does Vizimpro contain as an active substance? The medication Vizimpro specifically contains the active substance Dacomitinib. Is Dacomitinib FDA approved drug? Yes, Dacomitinib is an FDA approved drug. What should I avoid during treatment with Dacomitinib? You should minimize exposure to sunlight. This medication can cause skin reactions. How much does vizimpro cost? The vizimpro price in India usually may vary depending on the wholesaler/pharmacy you visit and of course the brand you choose. What is the best price of Dacomitinib? Please contact Toll-free: +91 1800 889 1064|+919650877511 for dacomitinib price in India. We take guarantee of quality as well as delivery anywhere in the world as per the buyer’s requirements. Can I get Vizimpro (Dacomitinib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Vizimpro (Dacomitinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Reviews

There are no reviews yet.

Be the first to review “Dacomitinib”

Your email address will not be published.

×